Last updated: 15 February 2024 at 5:48pm EST

Fang Ni Net Worth




The estimated Net Worth of Fang Ni is at least $769 Thousand dollars as of 21 December 2022. Mr. Ni owns over 56,363 units of Black Diamond Therapeutics Inc stock worth over $768,635 and over the last 3 years he sold BDTX stock worth over $0. In addition, he makes $0 as Chief Business Officer at Black Diamond Therapeutics Inc.

Mr. Ni BDTX stock SEC Form 4 insiders trading

Fang has made over 2 trades of the Black Diamond Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 56,363 units of BDTX stock worth $72,145 on 21 December 2022.

The largest trade he's ever made was buying 56,363 units of Black Diamond Therapeutics Inc stock on 21 December 2022 worth over $72,145. On average, Fang trades about 16,273 units every 35 days since 2022. As of 21 December 2022 he still owns at least 125,389 units of Black Diamond Therapeutics Inc stock.

You can see the complete history of Mr. Ni stock trades at the bottom of the page.





Fang Ni biography

Fang Ni serves as Chief Business Officer of the Company. Fang joins Black Diamond most recently from Versant Ventures, where he served as Principal and member of the investment team. He was Black Diamond's founding Chief Business Officer following the Company's Versant-led Series A financing, making critical contributions to Black Diamond's corporate and business strategy. While at Versant, Fang also served as Interim Chief Business Officer for several new ventures, including Monte Rosa Therapeutics and Bright Peak Therapeutics. He was previously a Global Business Development & Licensing director within Roche's Partnering organization, where he was responsible for leading transactions across oncology, immunology, and infectious and rare diseases. Fang earned a Doctor of Pharmacy degree from Purdue University and then completed a post-doctoral fellowship at Rutgers University



What's Fang Ni's mailing address?

Fang's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at Black Diamond Therapeutics Inc

Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah, and Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.



What does Black Diamond Therapeutics Inc do?

black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.



What does Black Diamond Therapeutics Inc's logo look like?

Black Diamond Therapeutics Inc logo

Complete history of Mr. Ni stock trades at Black Diamond Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
21 Dec 2022 Fang Ni
SEE REMARKS
Buy 56,363 $1.28 $72,145
21 Dec 2022
125,389
29 Jun 2022 Fang Ni
SEE REMARKS
Buy 25,000 $2.44 $61,000
29 Jun 2022
69,026


Black Diamond Therapeutics Inc executives and stock owners

Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include: